As the industry's most comprehensive NASH forum, the NASH Summit returns with an unrivalled depth and breadth of cutting-edge NASH science from drug discovery through to late stage clinical development.
Across 3 parallel streams of learning, 48 expert speakers including Gilead, Allergan and Novartis will share advances in:
• Validating non-invasive biomarkers to confidently stratify patients and enhance clinical response
• Evaluating the scientific rationale behind combination therapy for more effective treatment
• Conclusively comparing in vitro and in vivo models to better recapitulate human NASH and confidently progress into the clinic
Join 150+ drug developers from 120+ organizations at this focused discussion and networking forum. Address this huge unmet clinical need and gain actionable insights to propel your candidate to therapeutic success.